Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 22;17:11795549231199915. doi: 10.1177/11795549231199915

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — High SPAG5 expression in LUAD is associated with an unfavorable prognosis. (A and B) Survival analysis of the TCGA data set using the GEPIA database reveals that LUAD patients with high SPAG5 expression exhibit significantly worse OS (P = .0020) and progression-free survival (P = .0337). (C and D) Survival analysis of the GSE31210 data set using the PrognoScan website indicates that LUAD patients with high SPAG5 expression show significantly poorer RFS (P = .0007) and a tendency toward reduced OS (P = .0572). (E and F) Survival analysis of LUAD data in the Kaplan-Meier plotter database demonstrates a substantial decrease in OS (P = 2.5e−10) and PFS (P = 1.2e−9) among patients with high SPAG5 expression. GEPIA indicates Gene Expression Profiling Interactive Analysis; LUAD, lung adenocarcinoma; OS, overall survival; PFS, progression-free survival; SPAG5, sperm-associated antigen 5; TCGA, The Cancer Genome Atlas; RFS, relapse-free survival.